Drug delivery systems in urology—getting “smarter”

Farokhzad, Omid C.; Dimitrakov, Jordan D.; Karp, Jeffrey M.; Khademhosseini, Ali; Freeman, Michael; Langer, Robert

doi:10.1016/j.urology.2006.03.069

Cited by 30 publications

(20 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, the plot of peak potential versus pH showed a linear segment at pH 3.2. This intersection point of the curve is found to be close to the pKa value of GMB (3.6) [16]. This could be attributed to changes in protonation of acid-base properties of the molecule.…”

Section: Electrochemical Oxidation Of Gmbsupporting

confidence: 59%

Electrochemical studies and spectroscopic investigations on the interaction of an anticancer drug with DNA and their analytical applications

Kalanur

Katrahalli

Seetharamappa

2009

Journal of Electroanalytical Chemistry

160

View full text Add to dashboard Cite

Section: Electrochemical Oxidation Of Gmbsupporting

confidence: 59%

Electrochemical studies and spectroscopic investigations on the interaction of an anticancer drug with DNA and their analytical applications

Kalanur

Katrahalli

Seetharamappa

2009

Journal of Electroanalytical Chemistry

160

View full text Add to dashboard Cite

“…Use of elastomeric polymers in fabrication of device can help sculpt a cylindrical shape that is streamlined for easy instillation, which after insertion reverses to a different retentive shape 39 . Several factors influence the diffusion mediated temporal release of the drug from device including aqueous permeability of the polymer, rate of polymer degradation and size of the orifice that releases the drug 40 .…”

Section: Major Challenges To Intravesical Therapymentioning

confidence: 99%

Advances in intravesical therapy for urinary tract disorders

Tyagi

Kashyap

Hensley

et al. 2015

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Introduction Intravesical therapy is a valuable option in the clinical management of urinary tract disorders such as interstitial cystitis/ painful bladder syndrome (IC/PBS) and refractory overactive bladder. This review will cover the latest advances in this field using polymer and liposomes as delivery platform for drugs, protein and nucleic acids. Areas covered This review summarizes the significance of intravesical therapy for lower urinary tract disorders. The recent advancement of liposomes as a drug delivery platform for botulinum toxin, tacrolimus and small interfering RNA is discussed. The importance of polymers forming indwelling devices and hydrogels are also discussed, where all preparations improved efficacy parameters in rodent models. Clinical experience of treating IC/PBS with indwelling devices and liposomes are summarized and preclinical evidence about the downregulation of target gene expression in rodent bladder with liposomes complexed with siRNA is also reviewed. Expert opinion There have been several advances in the field of intravesical therapy for improving clinical outcomes. One of the most promising research avenues is the repurposing of drugs, given previously by other routes of administration, such as tacrolimus. Intravesical therapy also opens up novel therapeutic targets with improved efficacy and safety for underactive bladder.

show abstract

“…The dosage unit would thus be expected to possess adequate mechanical resistance characteristics when taking on the cumbersome retentive configuration. Evolution from a smaller to a larger size may result from differing physical phenomena, such as water‐swelling occurring on glass‐rubber transition, osmotically‐induced water uptake or return to an originally bulkier shape, for example, because of unfolding and/or elastic behavior upon discontinuation of a compressive external force, or else on account of inherent shape memory properties of component materials …”

Section: Introductionmentioning

confidence: 99%

Retentive drug delivery systems based on shape memory materials

Maroni

Melocchi

Gazzaniga

2019

J of Applied Polymer Sci

View full text Add to dashboard Cite

Retentive drug delivery systems are intended for prolonged residence and release inside hollow organs of the body, in pursuit of either local or systemic therapeutic goals. Because of the relatively long‐lasting period of time they could cover during operation, a primary advantage arising from their use would lie in reduced dosing frequency, thereby improving the overall adherence of patients to prescribed medication regimens. The treatment of numerous pathologies that affect the urinary bladder and the stomach could especially benefit from viability of such delivery technologies. Moreover, by making use of effective gastroretentive dosage forms, the bioavailability of drugs that are preferably absorbed from the upper gastrointestinal tract could be increased. Expansion of devices following administration is often exploited for retention purposes, and several formulation strategies have been proposed in this respect. Innovative applications of shape memory materials have also been explored, highlighting the great inherent potential for facing the challenges involved. © 2019 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2020, 137, 48798.

show abstract

Drug delivery systems in urology—getting “smarter”

Cited by 30 publications

References 46 publications

Electrochemical studies and spectroscopic investigations on the interaction of an anticancer drug with DNA and their analytical applications

Electrochemical studies and spectroscopic investigations on the interaction of an anticancer drug with DNA and their analytical applications

Advances in intravesical therapy for urinary tract disorders

Retentive drug delivery systems based on shape memory materials

Contact Info

Product

Resources

About